Primary gastric diffuse large B-cell Lymphoma (DLBCL): Analyses of prognostic factors and value of pretreatment FDG-PET scan

European Journal of Haematology

Volumn 84, Issue 6, 2010, Pages 493-498

  Chihara, Dai ^a   Oki, Yasuhiro ^a   Ine, Shouji ^a   Kato, Harumi ^a   Onoda, Hiroshi ^a   Taji, Hirofumi ^a   Kagami, Yoshitoyo ^a   Yamamoto, Kazuhito ^a   Morishima, Yasuo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Fluorodeoxyglucose positron emission tomography; Gastric diffuse large B cell lymphoma; Hemoglobin; Rituximab; Serum albumin

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRECTOMY; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; STOMACH LYMPHOMA; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HEMOGLOBINS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROGNOSIS; RADIOPHARMACEUTICALS; SERUM ALBUMIN; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; VINCRISTINE; YOUNG ADULT;

EID: 77952603087     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01426.x     Document Type: Article

References (29)

1. d'Amore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen MK, Andersen E, Pedersen NT, Mortensen LS. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol 1994 12 (8 1673 1684.
2. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993 342 (8871 571 574.
3. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995 345 (8965 1591 1594.
4. Maor MH, Velasquez WS, Fuller LM, Silvermintz KB. Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma. J Clin Oncol 1990 8 (2 266 271.
5. Shchepotin IB, Evans SR, Shabahang M, Chorny V, Buras RR, Korobko V, Zadorozhny A, Nauta RJ. Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients. Ann Surg Oncol 1996 3 (3 277 284.
6. Rabbi C, Aitini E, Cavazzini G, Cantore M, Forghieri ME, Pari F, Zamagni D, Mambrini A, Amadori M, Smerieri F. Stomach preservation in low-and high-grade primary gastric lymphomas: preliminary results. Haematologica 1996 81 (1 15 9.
7. Coiffier B, Salles G. Does surgery belong to medical history for gastric lymphomas? Ann Oncol 1997 8 (5 419 421.
8. Binn M, Ruskone-Fourmestraux A, Lepage E, Haioun C, Delmer A, Aegerter P, Lavergne A, Guettier C, Delchier JC. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol 2003 14 (12 1751 1757.
9. Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jager U, Puspok A, Osterreicher C, Zielinski CC. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol 2002 13 (7 1094 1098.
10. Wohrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol 2004 15 (7 1086 1090.
11. Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. (18)F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2009. [Epub ahead of print].
12. Phongkitkarun S, Varavithya V, Kazama T, Faria SC, Mar MV, Podoloff DA, Macapinlac HA. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 2005 11 (46 7284 7289.
13. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978 42 (2 693 707. (Pubitemid 8405865) (Pubitemid 8405865)
14. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994 12 (6 1169 1176.
15. Ogura M, Kagami Y, Taji H, Suzuki R, Miura K, Takeuchi T, Morishima Y. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 2003 77 (5 503 511.
16. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001 19 (18 3874 3883.
17. Koch P, Probst A, Berdel WE, et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005 23 (28 7050 7059.
18. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Eng J Med 1998 339 (21 1506 1514.
19. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma. 2009 50 (12 1999 2004.
20. Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008 49 (3 462 469.
21. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006 107 (12 4643 4649.
22. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008 111 (9 4463 4470.
23. Miller TP, Spier CM, Rimsza L. Diffuse aggressive histologies of non-hodgkin lymphoma: treatment and biology of limited disease. Semin Hematol 2006 43 (4 207 212.
24. Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007 110 (1 29 36.
25. Radan L, Fischer D, Bar-Shalom R, Dann EJ, Epelbaum R, Haim N, Gaitini D, Israel O. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging 2008 35 (8 1424 1430.
26. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971 31 (11 1860 1861.
27. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994 5 (5 397 400.
28. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Eng J Med 1993 329 (14 987 994.
29. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 (1 275 282.